Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302845 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03302845 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT03302845, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This drug-drug interaction study will evaluate the impact of two different acid reducing agents (from two different drug classes) co-administered with a single dose of telotristat ethyl.
Interventions
- DRUG Omeprazole 40 MG
- DRUG Famotidine 40 mg
- DRUG Telotristat ethyl 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302845
The ClinicalTrials.gov registry entry for NCT03302845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Omeprazole 40 MG is the first listed.
NCT03302845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302845 about?
NCT03302845 is a clinical study titled "A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects". This drug-drug interaction study will evaluate the impact of two different acid reducing agents (from two different drug classes) co-administered with a single dose of telotristat ethyl.
What is the current status of trial NCT03302845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-09-21. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT03302845?
The interventions under investigation include: Omeprazole 40 MG (DRUG), Famotidine 40 mg (DRUG), Telotristat ethyl 250 mg (DRUG).
Who is sponsoring clinical trial NCT03302845?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.